Navigation Links
Alsius Corporation to Host First Quarter 2008 Financial Results Conference Call on May 15, 2008

IRVINE, Calif., May 8 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), the worldwide leader in intravascular temperature management (IVTM(TM)) therapies for critically ill patients, today announced that it will hold a conference call to discuss the Company's first quarter results and provide a corporate update. Bill Worthen, president and CEO, and Brett Scott, CFO, will host the call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Thursday, May 15. A press release for the first quarter ended March 31, 2008 will be released following the market close on May 15.

To participate in the live call by telephone, please dial 877-545-1489 from the U.S. or +1-719-325-4930 for international callers. In addition, the live conference call is being webcast and can be accessed via the "Investor Relations" section of the Company's website at Beginning 90 minutes after the conference call concludes, a replay will be available on Alsius' website or by dialing 888-203-1112 from the U.S. or +1-719-457-0820 internationally, and entering passcode 3084937 when prompted. The telephone replay will be available through May 31, 2008.

About Alsius

Alsius, headquartered in Irvine, Calif., is a medical device company that develops, manufactures and sells proprietary products to precisely control patient temperature in hospital critical care settings. Controlling body temperature, through cooling and warming, is becoming the standard of care for patients in select critical conditions and those undergoing a variety of surgical procedures. Alsius markets a comprehensive suite of catheter-based intravascular temperature management products that address the need for effective, accurate, easy-to-use and cost-effective control of body temperature in critical care patients. For more information, visit

Safe Harbor

This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking. Such forward looking statements, based upon the current beliefs and expectations of Alsius' management, are subject to risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The information set forth herein should be read in light of such risks. Additional information concerning such risks and uncertainties are contained in Alsius' filings with the Securities and Exchange Commission, which can be accessed electronically on the Securities and Exchange Commission website at or on the Investor Relations section of Alsius' website at

SOURCE Alsius Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alsius Corporation to Host Fourth Quarter and Year-End 2007 Financial Results Conference Call/Webcast on March 13, 2008
2. Mac-Gray Corporation Announces First-Quarter 2008 Financial Results
3. MannKind Corporation Reports First Quarter Financial Results
4. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
5. BioElectronics Corporation Receives Major Orders From Italian Distributor
6. Oxford Finance Corporation and Comerica Bank Provide $15 Million Loan Facility to VisualSonics Inc.
7. MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 5, 2008
8. Syndexa Pharmaceuticals Corporation and ChemDiv, Inc. Announce Discovery Collaboration
9. Dialysis Corporation of America Announces First Quarter 2008 Earnings Release Date
10. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
11. LifeCell Corporation Schedules First Quarter 2008 Financial Results Conference Call; April 24, 2008 at 10:00 A.M. Eastern
Post Your Comments:
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... and CEO of Neurocrine Biosciences, will be presenting at ... New York . .   ... approximately 5 minutes prior to the presentation to download ... presentation will be available on the website approximately one ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
Breaking Biology Technology:
(Date:11/17/2015)...  Vigilant Solutions announces today that Mr. Dick ... --> --> Mr. ... partnership at TPG Capital, one of the largest global ... in revenue.  He founded and led TPG,s Operating Group, ... from 1997 to 2013.  In his first role, he ...
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... 2015   MedNet Solutions , an innovative SaaS-based eClinical ... is pleased to announce that it will be a Sponsor ... event, to be held November 17-19 in Hamburg ... demonstrations of iMedNet , MedNet,s easy-to-use, proven ... has been able to deliver time and cost savings ...
Breaking Biology News(10 mins):